series-a
Stage
2020
Founded
3
Investors
About
Rectify Pharma is developing disease-modifying precision therapeutics called Positive Functional Modulators (PFMs) that restore the function of ABC transporter proteins to treat serious genetic diseases affecting organs such as the lungs, liver, GI tract, eye and central nervous system. The company focuses on oral small-molecule modulators to correct loss-of-function mutations in the ABC transporter family.
Explore Rectify Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.